The efficacy of an extract obtained from the non-edible parts of pomegranates.
FDA accept NextPoint Therapeutics IND for HHLA2 targeting mAb – Pharmaceutical Technology
Share this article Nextpoint’s drug candidate is being investigated to treat patients with solid tumours that express tumour antigen HHLA2, such as some breast and